A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Thioureidobutyronitrile (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Innovation Pharmaceuticals
- 10 May 2017 According to a Cellceutix media release, this trial is expected to complete in 2H2017.
- 17 Feb 2017 Status changed from active, no longer recruiting to recruiting.
- 16 Feb 2017 According to a Cellceutix media release, member of the National Academy of Sciences has helped designing this trial.